Kundranda, Madappa
2 papers on CoChatORCID 0000-0002-9237-2666
Most cited papers
- Verified
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy
Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers
Cited by 277
- Verified
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 259
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free